4/A: QuidelOrtho Director Kenneth F. Buechler Amended Filing Reveals RSU Grants

Kenneth F. Buechler, a director at QuidelOrtho Corp, amended a previous filing to include the grant of restricted stock units (RSUs) received in lieu of cash payments.

Summary

• This is an amendment to a Form 4 filing by Kenneth F. Buechler, a director at QuidelOrtho Corp.
• The amendment includes the grant of Converted and Premium Restricted Stock Units (RSUs) to Buechler on May 22, 2024.
• The RSUs were received in lieu of cash payments for retainer and Board of Director service-related fees under a deferred compensation program.
• Buechler received 3,873 Converted RSUs and 1,161 Premium RSUs.
• Each RSU represents the right to receive one share of QuidelOrtho Corporation common stock.
• 968 of the Converted RSUs vested on May 22, 2024, with subsequent vesting dates on August 22, 2024, November 22, 2024, and February 22, 2025 (969 shares).
• The Premium RSUs vest on May 22, 2025.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding director compensation, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The grant of RSUs to a director aligns their interests with those of shareholders.
• The deferred compensation program allows directors to accumulate company stock over time.

Future Outlook

Release of vested restricted stock units will occur according to the elected deferral schedule.

Industry Context

Director compensation through equity grants is a common practice to align management's interests with shareholders in the healthcare industry.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across publicly traded companies, including those in the diagnostics and healthcare sectors.
• Companies like Abbott Laboratories, Danaher Corporation, and Thermo Fisher Scientific also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and amounts of RSUs granted to QuidelOrtho's directors would need to be compared to those of peer companies to determine if they are within industry norms.

Stakeholder Impact

• Shareholders may view the RSU grants positively as they align director interests with company performance.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates